Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04529772 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04529772 · ClinicalTrials.gov record · last posted 2026-06-25

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

Study acronym: ESCALADE
StatusActive, Not Recruiting
PhasePhase 3
Started2020-10-08
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects ≤75 years of age with previously untreated non-germinal center diffuse large B-cell lymphoma.

Amendment record 43 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 43 times since 2020-08-25; most recent amendment 2026-06-24. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-03-11
Status change Recruiting→Active, Not Recruitingv34
2020-11-06
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT04529772
Lead Sponsor Acerta Pharma BV
Collaborators: AstraZeneca
Conditions Diffuse Large B-Cell Lymphoma
Enrollment 611 participants
Start Date 2020-10-08
Primary Completion 2027-02-22 (estimated)
Study Completion 2027-02-22 (estimated)
Updated on ClinicalTrials.gov 2026-06-25